RSS   Newsletter   Contact   Advertise with us
Post Online Media

Halozyme names Mark J. Gergen as chief operating officer

HalozymeHalozyme Therapeutics, Inc., a biotechnology company, named biotech veteran Mark J. Gergen as senior vice president and chief operating officer.

Mr. Gergen joins Halozyme most recently from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions.

READ MORE Halozyme names Michael J. Labarre as chief scientific officer

He executed multiple successful partnerships, collaborations and licensing agreements.

Before Mirati, Mr. Gergen spent 7 years at Amylin Pharmaceuticals as a member of the executive committee reporting to the CEO, where he led corporate development and alliances.

Prior to Amylin, Mr. Gergen held senior management roles for Cardionet and Advanced Tissue Sciences, as well as the large group purchasing organization, Premier, and medical device pioneer, Medtronic.

He earned his B.A. in Business Administration from Minot State University in North Dakota and J.D. from the University of Minnesota Law School.




What to read next



 LATEST MOVES FROM California 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy